(Q28282189)

English

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

scientific article

In more languages

Statements

scholarly article

0 references

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study (English)

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

15

object named as

Olivier Rixe

0 references

author name string

Jean-Philippe Spano

1

0 references

Catherine Chodkiewicz

2

0 references

Joan Maurel

3

0 references

Ralph Wong

4

0 references

Harpreet Wasan

5

0 references

Carlo Barone

6

0 references

Richard Létourneau

7

0 references

Emilio Bajetta

8

0 references

Yazdi Pithavala

9

0 references

Paul Bycott

10

0 references

Peter Trask

11

0 references

Katherine Liau

12

0 references

Alejandro D Ricart

13

0 references

Sinil Kim

14

0 references

language of work or name

0 references

publication date

21 June 2008

0 references

0 references

371

0 references

2101-8

0 references

9630

0 references

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatic cancer and thromboembolic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960661-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60661-3

0 references

release_m6mxe6qlkrfxhairchzhlf5qjq

1 reference

https://api.fatcat.wiki/v0/release/m6mxe6qlkrfxhairchzhlf5qjq

24 November 2022

based on heuristic

mapped directly with Wikidata item

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28282189&oldid=1836714012"